Cylapril weight-loss claim halted
This article was originally published in The Tan Sheet
Executive Summary
The Electronic Retailing Self-Regulation Program recommends Adrenal Fatigue Institute discontinue claims that its supplement Cylapril helps consumers "lose the weight in just two easy steps," according to a June 24 report. The marketer failed to substantiate weight-loss claims during a routine review by ERSP. The firm agreed to discontinue the claims and claims that Cylapril is the "only product of its kind." The marketer supported claims that the supplement improves adrenal functioning, metabolism and fatigue, added ERSP
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.